SRNE News and Press, Sorrento Therapeutics Inc. From 01/08/21

The Robinhood app is popular among millennial investors. And as the Covid-19 pandemic focused attention on the biotech industry last year, many young investors rushed to bet on the sector. Though market hype has lately helped usher many biotech stocks onto the Robinhood 100 list (of most popu...

GX Acquisition Corp. (GXGX) has agreed to combine with Celularity Inc., a clinical-stage biotechnology company. The transaction expected in Q2 2021 will make GX Acquisition Corp. being renamed Celularity Inc.The common stock and warrants of the special purpose acquisition company are exp...

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that a Marketing Authorization Application has been submitted by its agents in Mexico to Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), th...

Looking For The Best Coronavirus Stocks To Add To Your 2021 Watchlist? With cases of novel coronavirus showing no signs of stopping, investors are starting to pull out a list of the coronavirus stocks to watch. Unfortunately, the disease has claimed over 1.7 million lives around...

Sorrento Therapeutics (SRNE) has submitted Emergency Use Authorization ((EUA)) application to the FDA for its COVI-STIX rapid diagnostic test for the detection of SARS-CoV-2 virus nucleocapsid antigen in nasal samples of patients. In testing conducted to date, COVI-STIX has provided results w...

SAN DIEGO, Dec. 22, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that an Emergency Use Authorization (EUA) Application has been submitted to the US Food and Drug Administration for its COVI-STIX rapid diagnostic test for the detection of th...

Palm Beach, FL – December 21, 2020 – Since the global outbreak that triggered the pandemic, scientists around the world have been working on potential treatments and vaccines for the new coronavirus disease known as COVID-19… and they have been making progress at a rapi...

Sorrento Therapeutics (NASDAQ: SRNE) hasn't released data from a phase 1 clinical trial testing STI-1499, which also goes by COVI-GUARD, its first-generation antibody treatment targeting the coronavirus that causes COVID-19. But the biotech is already moving on to its next-gener...

Sorrento Therapeutics ([[SRNE]] +4.1%) nabs FDA sign-off for its Phase 1 trial for intravenous ((IV)) STI-2020 (COVI-AMG) that will evaluate the safety, pharmacokinetics and efficacy of a single injection of STI-2020 in healthy volunteers and outpatient COVID-19 patients with mild s...

FDA has granted clearance for the commencement of Phase 1 clinical trials of STI-2020 (COVI-AMG TM ) in healthy volunteers and COVID-19 patients with mild symptoms. STI-2020, a monoclonal antibody, has been engineered for ultra-high potency, which potentially translates to a small...